Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6286 AL 6300

Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment

Habert MO, Horn JF, Sarazin M, Lotterie JA, Puel M, Onen F, Zanca M, Portet F, Touchon J, Verny M, Mahieux F, Giron A, Fertil B, Dubois B.

Neurobiol Aging. 2011 Jan;32(1):15-23. doi: 10.1016/j.neurobiolaging.2009.01.013. Epub 2009 Feb 27.

Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment

Molinuevo JL, Berthier ML, Rami L.

Arch Gerontol Geriatr. 2011 Jan-Feb;52(1):18-22. doi: 10.1016/j.archger.2009.11.004. Epub 2009 Nov 30.

Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease

Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J.

Int J Geriatr Psychiatry. 2011 Feb;26(2):150-7. doi: 10.1002/gps.2507.

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?

Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; DIADS-2 Research Group.

Int J Geriatr Psychiatry. 2011 Jun;26(6):573-83. doi: 10.1002/gps.2565.

Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients

Keller C, Kadir A, Forsberg A, Porras O, Nordberg A.

J Alzheimers Dis. 2011;24(1):109-23. doi: 10.3233/JAD-2010-101290.

Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population

Van Puyvelde K, Mets T; RODOS Study Group.

Geriatr Gerontol Int. 2011 Jul;11(3):256-61. doi: 10.1111/j.1447-0594.2010.00674.x. Epub 2011 Jan 4.

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative

Schneider LS, Insel PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Jan;68(1):58-66. doi: 10.1001/archneurol.2010.343.

Alzheimer's disease: future treatments

Morley JE.

J Am Med Dir Assoc. 2011 Jan;12(1):1-7. doi: 10.1016/j.jamda.2010.10.008.

Effect of memantine on resting state default mode network activity in Alzheimer's disease

Lorenzi M, Beltramello A, Mercuri NB, Canu E, Zoccatelli G, Pizzini FB, Alessandrini F, Cotelli M, Rosini S, Costardi D, Caltagirone C, Frisoni GB.

Drugs Aging. 2011 Mar 1;28(3):205-17. doi: 10.2165/11586440-000000000-00000.

Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study

Frölich L, Ashwood T, Nilsson J, Eckerwall G; Sirocco Investigators.

J Alzheimers Dis. 2011;24(2):363-74. doi: 10.3233/JAD-2011-101554.

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease

Grossberg G, Meng X, Olin JT.

Am J Alzheimers Dis Other Demen. 2011 Feb;26(1):65-71. doi: 10.1177/1533317510391240.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias

Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ; WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias.

World J Biol Psychiatry. 2011 Feb;12(1):2-32. doi: 10.3109/15622975.2010.538083.

Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type

Pinto T, Lanctôt KL, Herrmann N.

Ageing Res Rev. 2011 Sep;10(4):404-12. doi: 10.1016/j.arr.2011.01.003. Epub 2011 Feb 1.

"Lest we forget you--methylene blue..."

Schirmer RH, Adler H, Pickhardt M, Mandelkow E.

Neurobiol Aging. 2011 Dec;32(12):2325.e7-16. doi: 10.1016/j.neurobiolaging.2010.12.012. Epub 2011 Feb 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias